Cumberland Pharms Drug Patent Portfolio

Cumberland Pharms owns 2 orange book drugs protected by 17 US patents Given below is the list of Cumberland Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8952065 Acetylcysteine composition and uses thereof 10 Feb, 2035
Active
US8722738 Acetycysteine compositions and methods of use thereof 06 Apr, 2032
Active
US11806400 Injectable ibuprofen formulation 16 Mar, 2032
Active
US9072661 Injectable ibuprofen formulation 16 Mar, 2032
Active
US9072710 Injectable ibuprofen formulation 16 Mar, 2032
Active
US9327028 Acetylcysteine compositions and methods of use thereof 21 Jul, 2031
Active
US9012508 Administration of intravenous ibuprofen 14 Sep, 2030
Active
US8735452 Treating patients with intravenous ibuprofen 30 Sep, 2029
Active
US8871810 Treating critically ill patients with intravenous ibuprofen 30 Sep, 2029
Active
US9114068 Treating patients with intravenous ibuprofen 30 Sep, 2029
Active
US9138404 Treating critically ill patients with intravenous ibuprofen 30 Sep, 2029
Active
US9295639 Treating critically ill patients with intravenous ibuprofen 30 Sep, 2029
Active
US9649284 Treating critically ill patients with intravenous ibuprofen 30 Sep, 2029
Active
US8148356 Acetylcysteine composition and uses therefor 21 May, 2026
Active
US8399445 Acetylcysteine composition and uses thereof 24 Aug, 2025
Active
US8653061 Acetylcysteine composition and uses thereof 24 Aug, 2025
Active
US6727286 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid 27 Nov, 2021 Expired


Given below is the list of recent legal activities going on the following drug patents of Cumberland Pharms.

Activity Date Patent Number
Patent litigations
Email Notification 07 Nov, 2023 US11806400
Recordation of Patent Grant Mailed 07 Nov, 2023 US11806400
Patent Issue Date Used in PTA Calculation 07 Nov, 2023 US11806400
Recordation of Patent eGrant 07 Nov, 2023 US11806400
Patent eGrant Notification 07 Nov, 2023 US11806400
Mail Patent eGrant Notification 07 Nov, 2023 US11806400
Email Notification 19 Oct, 2023 US11806400
Issue Notification Mailed 18 Oct, 2023 US11806400
Dispatch to FDC 06 Oct, 2023 US11806400
Application Is Considered Ready for Issue 06 Oct, 2023 US11806400
Issue Fee Payment Received 03 Oct, 2023 US11806400
Issue Fee Payment Verified 03 Oct, 2023 US11806400
Mail Notice of Allowance 27 Sep, 2023 US11806400
Notice of Allowance Data Verification Completed 25 Sep, 2023 US11806400
Payment of Maintenance Fee, 12th Year, Large Entity 20 Sep, 2023 US8148356 (Litigated)


Cumberland Pharms's Drug Patent Litigations

Cumberland Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 04, 2012, against patent number US9295639. The petitioner , challenged the validity of this patent, with Leo PAVLIV et al as the respondent. Click below to track the latest information on how companies are challenging Cumberland Pharms's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9295639 December, 2012 Decision
(17 Sep, 2015)
Leo PAVLIV et al


Cumberland Pharms's Family Patents

Cumberland Pharms drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 40.8% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Cumberland Pharms Drug List

Given below is the complete list of Cumberland Pharms's drugs and the patents protecting them.


1. Acetadote

Acetadote is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8952065 Acetylcysteine composition and uses thereof 10 Feb, 2035
(10 years from now)
Active
US8722738 Acetycysteine compositions and methods of use thereof 06 Apr, 2032
(7 years from now)
Active
US9327028 Acetylcysteine compositions and methods of use thereof 21 Jul, 2031
(6 years from now)
Active
US8148356 Acetylcysteine composition and uses therefor 21 May, 2026
(1 year, 6 months from now)
Active
US8399445 Acetylcysteine composition and uses thereof 24 Aug, 2025
(9 months from now)
Active
US8653061 Acetylcysteine composition and uses thereof 24 Aug, 2025
(9 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Acetadote's drug page


2. Caldolor

Caldolor is protected by 11 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11806400 Injectable ibuprofen formulation 16 Mar, 2032
(7 years from now)
Active
US9072661 Injectable ibuprofen formulation 16 Mar, 2032
(7 years from now)
Active
US9072710 Injectable ibuprofen formulation 16 Mar, 2032
(7 years from now)
Active
US9012508 Administration of intravenous ibuprofen 14 Sep, 2030
(5 years from now)
Active
US8735452 Treating patients with intravenous ibuprofen 30 Sep, 2029
(4 years from now)
Active
US8871810 Treating critically ill patients with intravenous ibuprofen 30 Sep, 2029
(4 years from now)
Active
US9114068 Treating patients with intravenous ibuprofen 30 Sep, 2029
(4 years from now)
Active
US9138404 Treating critically ill patients with intravenous ibuprofen 30 Sep, 2029
(4 years from now)
Active
US9295639 Treating critically ill patients with intravenous ibuprofen 30 Sep, 2029
(4 years from now)
Active
US9649284 Treating critically ill patients with intravenous ibuprofen 30 Sep, 2029
(4 years from now)
Active
US6727286 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid 27 Nov, 2021
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caldolor's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List